Alendronic acid (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Alendronic acid" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

8doi.org

2^nd place

3web.archive.org

1^st place

3semanticscholar.org

11^th place

8^th place

2drugs.com

399^th place

333^rd place

2clincalc.com

3,912^th place

2,496^th place

1canada.ca

1,712^th place

1,063^rd place

1books.google.com

3^rd place

1fda.gov

447^th place

338^th place

1merck.com

6,464^th place

5,671^st place

1usnews.com

634^th place

432^nd place

1washingtonpost.com

34^th place

27^th place

1worldcat.org

5^th place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 978-3-527-60749-5.

canada.ca

"Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Alendronate Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Sun K, Liu JM, Sun HX, Lu N, Ning G (January 2013). "Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies". Osteoporosis International. 24 (1): 279–286. doi:10.1007/s00198-012-2158-8. PMID 23052941. S2CID 12625687.
Haber SL, McNatty D (March 2012). "An evaluation of the use of oral bisphosphonates and risk of esophageal cancer". The Annals of Pharmacotherapy. 46 (3): 419–423. doi:10.1345/aph.1Q482. PMID 22333262. S2CID 38417272.
Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (August 2007). "A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics". Clinical Therapeutics. 29 (8): 1548–1558. doi:10.1016/j.clinthera.2007.08.008. PMID 17919538.
Lenart BA, Lorich DG, Lane JM (March 2008). "Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate". The New England Journal of Medicine. 358 (12): 1304–1306. doi:10.1056/NEJMc0707493. PMID 18354114. S2CID 26968573.
- Lay summary in: Gordon S (19 March 2008). "Fosamax Linked to Unusual Femur Fractures". U.S. News & World Report. Archived from the original on 16 April 2010.
- Weinstein RS, Roberson PK, Manolagas SC (January 2009). "Giant osteoclast formation and long-term oral bisphosphonate therapy". The New England Journal of Medicine. 360 (1): 53–62. doi:10.1056/NEJMoa0802633. PMC 2866022. PMID 19118304.
  - Lay summary in: Gardner A (31 December 2008). "Osteoporosis Drug Prompts Increase in Certain Bone Cells". Washington Post.
  - Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (February 2008). "An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?". Injury. 39 (2): 224–231. doi:10.1016/j.injury.2007.08.036. PMID 18222447.
  - Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. (June 2000). "Cellular and molecular mechanisms of action of bisphosphonates". Cancer. 88 (12 Suppl): 2961–2978. doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.3.co;2-c. PMID 10898340.
  - Shinkai I, Ohta Y (January 1996). "New drugs--reports of new drugs recently approved by the FDA. Alendronate". Bioorganic & Medicinal Chemistry. 4 (1): 3–4. doi:10.1016/0968-0896(96)00042-9. PMID 8689235.

drugs.com

"Alendronate Use During Pregnancy". Drugs.com. 22 August 2019. Retrieved 17 May 2020.
"Fosamax Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 2 February 2019.

fda.gov

accessdata.fda.gov

"Severe Pain with Osteoporosis Drugs". FDA Patient Safety News. March 2008. Archived from the original on 15 April 2014.

merck.com

"Fosamax product description" (PDF). Merck & Co.

nih.gov

pubmed.ncbi.nlm.nih.gov

Sun K, Liu JM, Sun HX, Lu N, Ning G (January 2013). "Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies". Osteoporosis International. 24 (1): 279–286. doi:10.1007/s00198-012-2158-8. PMID 23052941. S2CID 12625687.
Haber SL, McNatty D (March 2012). "An evaluation of the use of oral bisphosphonates and risk of esophageal cancer". The Annals of Pharmacotherapy. 46 (3): 419–423. doi:10.1345/aph.1Q482. PMID 22333262. S2CID 38417272.
Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (August 2007). "A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics". Clinical Therapeutics. 29 (8): 1548–1558. doi:10.1016/j.clinthera.2007.08.008. PMID 17919538.
Carini F, Barbano L, Saggese V, Monai D, Porcaro G (April 2012). "Multiple systemic diseases complicated by bisphosphonate osteonecrosis: a case report". Annali di Stomatologia. 3 (2 Suppl): 32–36. PMC 3512552. PMID 23285320.
Lenart BA, Lorich DG, Lane JM (March 2008). "Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate". The New England Journal of Medicine. 358 (12): 1304–1306. doi:10.1056/NEJMc0707493. PMID 18354114. S2CID 26968573.
- Lay summary in: Gordon S (19 March 2008). "Fosamax Linked to Unusual Femur Fractures". U.S. News & World Report. Archived from the original on 16 April 2010.
- Weinstein RS, Roberson PK, Manolagas SC (January 2009). "Giant osteoclast formation and long-term oral bisphosphonate therapy". The New England Journal of Medicine. 360 (1): 53–62. doi:10.1056/NEJMoa0802633. PMC 2866022. PMID 19118304.
  - Lay summary in: Gardner A (31 December 2008). "Osteoporosis Drug Prompts Increase in Certain Bone Cells". Washington Post.
  - Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (February 2008). "An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?". Injury. 39 (2): 224–231. doi:10.1016/j.injury.2007.08.036. PMID 18222447.
  - Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. (June 2000). "Cellular and molecular mechanisms of action of bisphosphonates". Cancer. 88 (12 Suppl): 2961–2978. doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.3.co;2-c. PMID 10898340.
  - Shinkai I, Ohta Y (January 1996). "New drugs--reports of new drugs recently approved by the FDA. Alendronate". Bioorganic & Medicinal Chemistry. 4 (1): 3–4. doi:10.1016/0968-0896(96)00042-9. PMID 8689235.
  ncbi.nlm.nih.gov
  - Carini F, Barbano L, Saggese V, Monai D, Porcaro G (April 2012). "Multiple systemic diseases complicated by bisphosphonate osteonecrosis: a case report". Annali di Stomatologia. 3 (2 Suppl): 32–36. PMC 3512552. PMID 23285320.
  - Weinstein RS, Roberson PK, Manolagas SC (January 2009). "Giant osteoclast formation and long-term oral bisphosphonate therapy". The New England Journal of Medicine. 360 (1): 53–62. doi:10.1056/NEJMoa0802633. PMC 2866022. PMID 19118304.
    - Lay summary in: Gardner A (31 December 2008). "Osteoporosis Drug Prompts Increase in Certain Bone Cells". Washington Post.
    dailymed.nlm.nih.gov
    - "Fosamax- alendronate sodium tablet". DailyMed. 16 April 2024. Retrieved 30 September 2024.

semanticscholar.org

api.semanticscholar.org

Sun K, Liu JM, Sun HX, Lu N, Ning G (January 2013). "Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies". Osteoporosis International. 24 (1): 279–286. doi:10.1007/s00198-012-2158-8. PMID 23052941. S2CID 12625687.
Haber SL, McNatty D (March 2012). "An evaluation of the use of oral bisphosphonates and risk of esophageal cancer". The Annals of Pharmacotherapy. 46 (3): 419–423. doi:10.1345/aph.1Q482. PMID 22333262. S2CID 38417272.
Lenart BA, Lorich DG, Lane JM (March 2008). "Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate". The New England Journal of Medicine. 358 (12): 1304–1306. doi:10.1056/NEJMc0707493. PMID 18354114. S2CID 26968573.
- Lay summary in: Gordon S (19 March 2008). "Fosamax Linked to Unusual Femur Fractures". U.S. News & World Report. Archived from the original on 16 April 2010.

usnews.com

health.usnews.com

Lenart BA, Lorich DG, Lane JM (March 2008). "Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate". The New England Journal of Medicine. 358 (12): 1304–1306. doi:10.1056/NEJMc0707493. PMID 18354114. S2CID 26968573.
- Lay summary in: Gordon S (19 March 2008). "Fosamax Linked to Unusual Femur Fractures". U.S. News & World Report. Archived from the original on 16 April 2010.

washingtonpost.com

Weinstein RS, Roberson PK, Manolagas SC (January 2009). "Giant osteoclast formation and long-term oral bisphosphonate therapy". The New England Journal of Medicine. 360 (1): 53–62. doi:10.1056/NEJMoa0802633. PMC 2866022. PMID 19118304.
- Lay summary in: Gardner A (31 December 2008). "Osteoporosis Drug Prompts Increase in Certain Bone Cells". Washington Post.

web.archive.org

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Severe Pain with Osteoporosis Drugs". FDA Patient Safety News. March 2008. Archived from the original on 15 April 2014.
Lenart BA, Lorich DG, Lane JM (March 2008). "Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate". The New England Journal of Medicine. 358 (12): 1304–1306. doi:10.1056/NEJMc0707493. PMID 18354114. S2CID 26968573.
- Lay summary in: Gordon S (19 March 2008). "Fosamax Linked to Unusual Femur Fractures". U.S. News & World Report. Archived from the original on 16 April 2010.

worldcat.org

search.worldcat.org

Tripathi DK (30 September 2013). Essentials of medical pharmacology (Seventh ed.). New Delhi. ISBN 978-9-350-25937-5. OCLC 868299888.{{cite book}}: CS1 maint: location missing publisher (link)